Clinical potential of VIP by modified Pharmaco-kinetics and delivery mechanisms

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 12, Issue 4, 2012, Pages 344-350

  Burian, Bernhard ^a   Ortner, Anna ^b   Prassl, Ruth ^c   Zimmer, Andreas ^d   Mosgoeller, Wilhelm ^e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^d UNIVERSITY OF GRAZ   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Asthma; Biodegradable particles; COPD; Liposomes; Pharmacokinetics; Proticles; VIP

Indexed keywords

CASPASE 3; CHEMOKINE; IK 312532; LIPOSOME; MATRIX METALLOPROTEINASE; NANOCARRIER; NANOPARTICLE; PROTAMINE; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE DERIVATIVE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; WHEAT GERM AGGLUTININ;

ASTHMA; AUTOIMMUNE DISEASE; BLOOD PRESSURE REGULATION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIABETES MELLITUS; DRUG TARGETING; ENTERITIS; ERECTILE DYSFUNCTION; HUMAN; INFLAMMATORY DISEASE; LIPOSOMAL GENE DELIVERY SYSTEM; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; PATHOLOGY; PNEUMONIA; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW;

ADMINISTRATION, INHALATION; ANIMALS; ASTHMA; DRUG CARRIERS; GASTROINTESTINAL AGENTS; HUMANS; HYPERTENSION, PULMONARY; LIPOSOMES; NANOPARTICLES; NEOPLASMS; NEUROPROTECTIVE AGENTS; PROTAMINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; VASOACTIVE INTESTINAL PEPTIDE; VASODILATOR AGENTS;

EID: 84870187751     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/187153012803832594     Document Type: Review

References (76)

1. Sreedharan, S.P.; Patel, D.R.; Huang, J.X. and Goetzl, E.J. (1993) Cloning and functional expression of a human neuroendocrine vasoactive intestinal peptide receptor. Biochem. Biophys. Res. Commun., 193, 546-553.
2. Usdin, T.B.; Bonner, T.I. and Mezey, E. (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology, 135, 2662-2680.
3. Vertongen, P.; Schiffmann, S.N.; Gourlet, P. and Robberecht, P. (1998) Autoradiographic visualization of the receptor subclasses for vasoactive intestinal polypeptide (VIP) in rat brain. Ann. N. Y. Acad. Sci., 865, 412-415.
4. Reubi, J.C. (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. N. Y. Acad. Sci., 921, 1-25.
5. Vaudry, D. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev., 52, 269-324.
6. Burian, B.; Storka, A.; Marzluf, B.A.; Yen, Y.C.; Lambers, C.; Robibaro, B.; Vonbank, K.; Mosgoeller, W. and Petkov, V. (2010) Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients. Peptides, 31, 603-608.
7. Ortner, A.; Wernig, K.; Kaisler, R.; Edetsberger, M.; Hajos, F.; Köhler, G.; Mosgoeller, W. and Zimmer, A. (2010) VPAC receptor mediated tumor cell targeting by protamine based nanoparticles. J. Drug Target, 18, 457-467.
8. Busto, R.; Prieto, J.C.; Bodega, G.; Zapatero, J.; Fogué, L. and Carrero, I. (2003) VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: a study in biopsy specimens. Peptides, 24, 429-436.
9. Moody, T.W.; Hill, J.M. and Jensen, R.T. (2003) VIP as a trophic factor in the CNS and cancer cells. Peptides, 24, 163-177.
10. Moody, T.W. and Jensen, R.T. (2006) Breast cancer VPAC1 receptors. Ann. N. Y. Acad. Sci., 1070, 436-439.
11. Ou, X.; Tan, T.; He, L.; Li, Y.; Li, J. and Kuang, A. (2005) Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor. Cancer Gene Ther., 12, 313-320.
12. Bienenstock, J.; Tomioka, M.; Matsuda, H.; Stead, R.H.; Quinonez, G.; Simon, G.T.; Coughlin, M.D. and Denburg, J.A. (1987) The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions. Int. Arch. Allergy Appl. Immunol., 82, 238-243.
13. Surrenti, C.; Renzi, D.; Garcea, M.R.; Surrenti, E. and Salvadori, G. (1993) Colonic vasoactive intestinal polypeptide in ulcerative colitis. J. Physiol., 87, 307-311.
14. Goetzl, E.J.; Xia, M.; Ingram, D.A.; Kishiyama, J.L.; Kaltreider, H.B.; Byrd, P.K.; Ichikawa, S. and Sreedharan, S.P. (1995) Neuropeptide signaling of lymphocytes in immunological responses. Int. Arch. Allergy Immunol., 107, 202-204.
15. Befus, A.D.; Mathison, R. and Davison, J. (1999) Integration of neuro-endocrine immune responses in defense of mucosal surfaces. Am. J. Trop Med. Hyg., 60, 26-34.
16. Filipsson, K.; Tornoe, K.; Holst, J. and Ahren, B. (1997) Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. J. Clin. Endocrinol. Metab., 82, 3093-3098.
17. Filipsson, K.; Pacini, G.; Scheurink, A.J. and Ahren, B. (1998) PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice. Am. J. Physiol., 274, E834-E842.
18. Petkov, V.; Mosgoeller, W.; Ziesche, R.; Raderer, M.; Stiebellehner, L.; Vonbank, K.; Funk, G.C.; Hamilton, G.; Novotny, C.; Burian, B. and Block, L.H. (2003) Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest., 111, 1339-1346
19. Leuchte, H.H.; Baezner, C.; Baumgartner, R.A.; Bevec, D.; Bacher, G.; Neurohr, C. and Behr, J. (2008) Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur. Respir. J., 32, 1289-1294.
20. Said, S.I. (2008) The vasoactive intestinal peptide gene is a key modulator of pulmonary vascular remodeling and inflammation. Ann. N. Y. Acad. Sci., 1144, 148-153.
21. Said, S.I.; Hamidi, S.A.; Dickman, K.G.; Szema, A.M.; Lyubsky, S.; Lin, R.Z.; Jiang, Y.P.; Chen, J.J.; Waschek, J.A. and Kort, S. (2007) Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation, 115, 1260-1268.
22. Hamidi, S.A.; Prabhakar, S. and Said, S.I. (2008) Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur. Respir. J., 31, 135-139.
23. St Hilaire, R.C.; Kadowitz, P.J. and Jeter, J.R. Jr. (2009) Adenoviral transfer of vasoactive intestinal peptide (VIP) gene inhibits rat aortic and pulmonary artery smooth muscle cell proliferation. Peptides, 30, 2323-2329.
24. Schmidt, D.T.; Rühlmann, E.; Waldeck, B.; Branscheid, D.; Luts, A.; Sundler, F. and Rabe, K.F. (2001) The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. Naunyn Schmiedebergs Arch. Pharmacol., 364, 314-320.
25. Groneberg, D.A.; Springer. J. and Fischer, A. (2001) Vasoactive intestinal polypeptide as mediator of asthma. Pulm. Pharmacol. Ther., 14, 391-401.
26. Tan, Y.R.; Yang, T.; Liu, S.P.; Xiang, Y.; Qu, F.; Liu, H.J. and Qin, X.Q. (2008) Pulmonary peptidergic innervation remodeling and development of airway hyperresponsiveness induced by RSV persistent infection. Peptides, 29, 47-56.
27. Liu, A.; Li, P.S. and Zhang, Z.J. (1993) A clinical study on determination of plasma vasoactive intestinal peptide and the relationship between plasma vasoactive intestinal peptide and bronchial responsiveness in asthmatics. Zhonghua Nei Ke Za Zhi, 32, 165-166.
28. Cardell, L.O.; Uddman, R. and Edvinsson, L. (1994) Low plasma concentrations of VIP and elevated levels of other neuropeptides during exacerbations of asthma. Eur. Respir. J., 7, 2169-2173.
29. Paul, S.; Said, S.I.; Thompson, A.B.; Volle, D.J.; Agrawal, D.K.; Foda, H. and de la Rocha, S. (1989) Characterization of autoantibodies to vasoactive intestinal peptide in asthma. J. Neuroimmunol., 23, 133-142.
30. Olopade, C.O.; Yu, J.; Abubaker, J.; Mensah, E. and Paul, S. (2006) Catalytic hydrolysis of VIP in pregnant women with asthma. J. Asthma, 43, 429-432.
31. Tang, H.; Welton, A. and Ganea, D. (1995) Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553. J. Interferon. Cytokine Res., 15, 993-1003.
32. Lindén, A.; Hansson, L.; Andersson, A.; Palmqvist, M.; Arvidsson, P.; Löfdahl, C.G.; Larsson, P. and Lötvall, J. (2003) Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma. Thorax, 58, 217-221.
33. Szema, A.M.; Hamidi, S.A.; Lyubsky, S.; Dickman, K.G.; Mathew, S.; Abdel-Razek, T.; Chen, J.J.; Waschek, J.A. and Said, S.I. (2006) Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am. J. Physiol. Lung Cell. Mol. Physiol., 291, L880-L886.
34. Palmer, J.B.; Cuss, F.M.; Warren, J.B.; Blank, M.; Bloom, S.R.; Barnes, P.J. (1986) Effect of infused vasoactive intestinal peptide on airway function in normal subjects. Thorax., 41, 663-666.
35. Morice, A.H. and Sever, P.S. (1986) Vasoactive intestinal peptide as a bronchodilator in severe asthma. Peptides, 7, 279-280.
36. Crimi, N.; Palermo, F.; Oliveri, R.; Palermo, B.; Vancheri, C.; Polosa, R. and Mistretta, A. (1988) Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction. J. Allergy Clin. Immunol., 82, 617-621.
37. Miotto, D.; Boschetto, P.; Bononi, I.; Zeni, E.; Cavallesco, G.; Fabbri, L.M. and Mapp, C.E. (2004) Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis. Eur. Respir. J., 24, 958-963.
38. Choi, J.Y.; Joo, N.S.; Krouse, M.E.; Wu, J.V.; Robbins, R.C.; Ianowski, J.P.; Hanrahan, J.W. and Wine, J.J. (2007) Synergistic airway gland mucus secretion in response to vasoactive intestinal peptide and carbachol is lost in cystic fibrosis. J. Clin. Invest., 11, 3118-3127.
39. Onoue, S.; Endo, K.; Ohmori, Y.; Yamada, S.; Kimura, R.; Yajima, T. and Kashimoto, K. (2004a) Long-acting analogue of vasoactive intestinal peptide, [R15, 20, 21, L17]-VIP-GRR (IK312532), protects rat alveolar L2 cells from the cytotoxicity of cigarette smoke. Regul. Pept., 123, 193-199.
40. Onoue, S.; Ohmori, Y.; Endo, K.; Yamada, S.; Kimura, R. and Yajima, T. (2004b) Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide attenuate the cigarette smoke extract-induced apoptotic death of rat alveolar L2 cells. Eur. J. Biochem., 271, 1757-1767.
41. Onoue, S.; Misaka, S.; Aoki, Y.; Karaki, S.; Kuwahara, A.; Ohide, A.; Mizumoto, T. and Yamada, S. (2010) Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats. Eur. J. Pharm. Sci., 41, 508-514.
42. Misaka, S.; Aoki, Y.; Karaki, S.; Kuwahara, A.; Mizumoto, T.; Onoue, S. and Yamada, S. (2010) Inhalable powder formulation of a stabilized vasoactive intestinal peptide (VIP) derivative: antiinflammatory effect in experimental asthmatic rats. Peptides, 31, 72-78.
43. Sergejeva, S.; Hoshino, H.; Yoshihara, S.; Kashimoto, K.; Lötvall, J. and Lindén, A. (2004) A synthetic VIP peptide analogue inhibits neutrophil recruitment in rat airways in vivo. Regul. Pept., 117, 149-154.
44. Gomariz, R.P. (2006) VIP-PACAP system in immunity: new insights for multitarget therapy. Ann. N. Y. Acad. Sci., 1070, 51-74.
45. Lucchini, R.E.; Facchini, F.; Turato, G.; Saetta, M.; Caramori, G.; Ciaccia, A.; Maestrelli, P.; Springall, D.R.; Polak, J.M.; Fabbri, L. and Mapp, C.E. (1997) Increased VIP-positive nerve fibers in the mucous glands of subjects with chronic bronchitis. Am. J. Respir. Crit. Care Med., 156, 1963-1968.
46. Kaltreider, H.B.; Ichikawa, S.; Byrd, P.K.; Ingram, D.A.; Kishiyama, J.L.; Sreedharan, S.P.; Warnock, M.L.; Beck, J.M. and Goetzl, E.J. (1997) Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma. Am. J. Respir. Cell Mol. Biol., 16, 133-144.
47. Guan, C.X.; Zhang, M.; Qin, X.Q.; Cui, Y.R.; Luo, Z.Q.; Bai, H.B. and Fang, X. (2006) Vasoactive intestinal peptide enhances wound healing and proliferation of human bronchial epithelial cells. Peptides, 27, 3107-3114.
48. Virgolini, I.; Raderer, M.; Kurtaran, A.; Angelberger, P.; Banyai, S.; Yang, Q.; Li, S.; Banyai, M.; Pidlich, J.; Niederle, B.; Scheithauer, W. and Valent, P. (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N. Engl. J. Med., 331, 1116-1121.
49. Heppeler, A.; Froidevaux, S.; Eberle, A.N. and Maecke, H.R. (2000) Receptor targeting for tumor localisation and therapy with radiopeptides. Curr. Med. Chem., 7, 971-994
50. Qu, Z.; Griffiths, G.L.; Wegener, W.A.; Chang, C.H.; Govindan, S.V.; Horak, I.D.; Hansen, H.J. and Goldenberg, D.M. (2005) Development of humanized antibodies as cancer therapeutics. Methods. 36, 84-95.
51. Virgolini, I.; Kurtaran, A.; Raderer, M.; Leimer, M.; Angelberger, P.; Havlik, E.; Li, S.; Scheithauer, W.; Niederle, B.; Valent, P.; et al. (1995) Vasoactive intestinal peptide receptor scintigraphy. J. Nucl. Med., 36, 1732-1739.
52. Kurtaran, A.; Leimer, M.; Kaserer, K.; Yang, Q.; Angelberger, P.; Niederle, B.; Virgolini, I. (1996) Combined use of 111In-DTPA-DPhe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC). Nucl. Med. Biol., 23, 503-507.
53. Virgolini, I.; Kurtaran, A.; Leimer, M.; Kaserer, K.; Peck-Radosavljevic, M.; Angelberger, P.; Hübsch, P.; Dvorak, M.; Valent, P. and Niederle, B. (1998) Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. J. Nucl. Med., 39, 1575-1579.
54. Ohmori, Y. (2006) Development of dry powder inhalation system of novel vasoactive intestinal peptide (VIP) analogue for pulmonary administration. Life Sci., 79, 138-143.
55. Bolin, D.R.; Michalewsky, J.; Wasserman, M.A. and O'Donnell, M. (1995) Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers, 37, 57-66.
56. Domschke, S.; Domschke, W.; Bloom, S.R.; Mitznegg, P.; Mitchell, S.J.; Lux, G. and Strunz, U. (1978) Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut., 19, 1049-1053.
57. Stiuso, P.; Marabotti, A.; Facchiano, A.; Lepretti, M.; Dicitore, A.; Ferranti, P. and Cartenì, M. (2006) Assessment of the conformational features of vasoactive intestinal peptide in solution by limited proteolysis experiments. Biopolymers, 81, 110-119.
58. Tam, E.K. and Caughey, G.H. (1990) Degradation of airway neuropeptides by human lung tryptase. Am. J. Respir. Cell Mol. Biol., 3, 27-32.
59. Onyüksel, H.; Ikezaki, H.; Patel, M.; Gao, X.P. and Rubinstein, I. (1999) A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm. Res., 16, 155-160.
60. Ashok, B.; Rubinstein, I.; Tsueshita, T. and Onyüksel, H. (2004) Effects of peptide molecular mass and PEG chain length on the vasoreactivity of VIP and PACAP(1-38) in pegylated phospholipid micelles. Peptides, 25, 1253-1258.
61. Sethi, V.; Onyüksel, H. and Rubinstein, I. (2005) Liposomal vasoactive intestinal peptide. Methods Enzymol., 391, 377-395.
62. Hajos, F.; Stark, B.; Hensler, S.; Prassl, R. and Mosgoeller, W. (2008) Inhalable liposomal formulation for vasoactive intestinal peptide. Int. J. Pharm., 357, 286-294.
63. Stark, B.; Andreae, F.; Mosgoeller, W.; Edetsberger, M.; Gaubitzer, E.; Koehler, G. and Prassl, R. (2008) Liposomal vasoactive intestinal peptide for lung application: protection from proteolytic degradation. Eur. J. Pharm. Biopharm., 70, 153-164.
64. Lajavardi, L.; Camelo, S.; Agnely, F.; Luo, W.; Goldenberg, B.; Naud, M.C.; Behar-Cohen, F.; de Kozak, Y. and Bochot, A. (2009) New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J. Control. Release, 139, 22-30.
65. Wernig, K.; Griesbacher, M.; Andreae, F.; Hajos, F.; Wagner, J.; Mosgoeller, W. and Zimmer, A. (2008) Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles. J. Controlled Release, 130, 192-198.
66. Gololobov, G.; Noda, Y.; Sherman, S.; Rubinstein, I.; Baranowska-Kortylewicz, J. and Paul, S. (1998) Stabilization of vasoactive intestinal peptide by lipids. J. Pharmacol. Exp. Ther., 285, 753-758.
67. Stark, B.; Debbage, P.; Andreae, F.; Mosgoeller, W. and Prassl, R. (2007) Association of vasoactive intestinal peptide with polymergrafted liposomes: structural aspects for pulmonary delivery. Biochim. Biophys. Acta., 1768, 705-714.
68. Huang, M. and Rorstad, O.P. (1987) VIP receptors in mesenteric and coronary arteries: a radioligand binding study. Peptides, 8, 477-485.
69. Noda, Y. (1994) Partitioning of vasoactive intestinal polypeptide into lipid bilayers. Biochim. Biophysis. Acta., 1191, 324-330.
70. Sejourne, F.; Rubinstein, I.; Suzuki, H. and Alkan-Onyüksel, H. (1997) Development of a novel bioactive formulation of vasoactive intestinal peptide in sterically stabilized liposomes. Pharm. Res., 14, 362-365.
71. Onyüksel, H.; Ashok, B.; Dagar, S.; Sethi, V. and Rubinstein, I. (2003) Interactions of VIP with rigid phospholipid bilayers: implications for vasoreactivity. Peptides, 24, 281-286.
72. Onyüksel, H.; Sejourne, F.; Suzuki, H. and Rubinstein, I. (2006) Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension. Peptides, 27, 2271-2275.
73. Junghans, M.; Kreuter, J. and Zimmer, A. (2000) Antisense delivery using protamine-oligonucleotide particles. Nucleic Acids Res., 28, E45.
74. Fernandez-Montesinos, R. (2009) Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles. Nanomedicine (Lond)., 4, 919-930.
75. Gao, X.; Wu, B.; Zhang, Q.; Chen, J.; Zhu, J.; Zhang, W.; Rong, Z.; Chen, H. and Jiang, X. (2007) Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J. Control Rel., 121, 156-167.
76. Dribek, M.; Le Potier, I.; Rodrigues, A.; Pallandre, A.; Fattal, E. and Taverna, M. (2007) Determination of binding constants of vasoactive intestinal peptide to poly(amidoamine) dendrimers designed for drug delivery using ACE. Electrophoresis, 28, 2191-2200.